Good
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements match FDA label excerpts, including indication, IV bolus administration at end of hemodialysis, and the CaSR mechanism. Some administration specifics (infusion vs bolus; timing/dialyzer rinse-back details) are imprecise or potentially inaccurate, and one key label limitation (not studied/not recommended for non-hemodialysis CKD) is not clearly stated as such.
Category Scores
Accurate Statements
Parsabiv is administered intravenously.
Section 2.3/2.1: “administered by intravenous (IV) bolus injection …”
Parsabiv is used to treat secondary hyperparathyroidism in adults with chronic kidney disease on dialysis.
Section 1: “indicated … in adult patients with CKD on hemodialysis.”
Secondary hyperparathyroidism is a condition where the parathyroid glands become overactive, leading to high levels of parathyroid hormone.
Not explicitly provided in the label excerpts; however, this is consistent with the labeled disease area description. (No direct label text excerpt verifying this definition was supplied.)
Parsabiv works by binding to the calcium-sensing receptor on the parathyroid glands.
Section 12.1: “binds to the calcium-sensing receptor (CaSR)… on parathyroid chief cells.”
Binding to the calcium-sensing receptor reduces the secretion of parathyroid hormone.
Section 12.1: “Activation of the CaSR… decreases PTH secretion.”
Parsabiv is manufactured by Amgen.
Not present in the supplied label excerpts.
A serious risk associated with Parsabiv is hypocalcemia (low calcium levels in the blood).
Section 5.1: “PARSABIV lowers serum calcium and can lead to hypocalcemia, sometimes severe.”
Symptoms of hypocalcemia can include tingling or numbness in the hands, feet, or around the mouth, muscle cramps or spasms, and seizures.
Section 5.1: “can cause paresthesias, myalgias, muscle spasms, seizures…” (paresthesias corresponds to tingling/numbness).
Parsabiv is an active peptide mimetic of calcium.
Not explicitly provided in supplied excerpts; label excerpt describes calcimimetic agent and CaSR activation.
Parsabiv acts as a calcimimetic agent.
Section 12.1: “Etelcalcetide is a calcimimetic agent…”
Parsabiv binds to the calcium-sensing receptor on the parathyroid glands, thereby lowering parathyroid hormone levels.
Section 12.1: CaSR binding and decreased PTH secretion.
Unsupported Statements
The infusion typically lasts for 15 minutes.
No administration duration/timing (e.g., 15 minutes) is provided in the supplied label excerpts.
Parsabiv is infused into a vein by a healthcare professional.
Label excerpt specifies IV bolus injection and specific administration steps in the dialysis circuit; it does not state “infused” or “into a vein” phrasing or a general infusion workflow.
Parsabiv is manufactured by Amgen.
No manufacturer text is included in the supplied label excerpts.
Parsabiv is an active peptide mimetic of calcium.
Supplied excerpts do not use the phrase “peptide mimetic of calcium.” They describe etelcalcetide as a calcimimetic agent.
Other side effects of Parsabiv can include nausea, vomiting, diarrhea, and muscle pain.
The supplied adverse reaction excerpts list examples from Table 2 (e.g., blood calcium decreased, muscle spasms, hypocalcemia, paresthesia) but do not provide nausea/vomiting/diarrhea/“muscle pain” in the excerpts.
Its use in patients not on dialysis is not specified in the provided text.
The supplied label excerpt includes a limitation: not studied/recommended in CKD patients not on hemodialysis.
Contradictions
Low
AI Statement
Parsabiv is infused into a vein by a healthcare professional.
Label Reference
Section 2.1/2.3: “administered by intravenous (IV) bolus injection…” (bolus vs infusion).
Low
AI Statement
The infusion typically lasts for 15 minutes.
Label Reference
Section 2.1/2.3 describe IV bolus and dialysis-circuit timing; no 15-minute infusion duration is stated.
Important Omissions
Contraindications: hypersensitivity to etelcalcetide or excipients.
Importance:
Moderate
Drug interaction limitation: switching from cinacalcet to PARSABIV requires discontinuing cinacalcet for at least 7 days; concurrent use with another oral calcium-sensing receptor agonist may cause severe life-threatening hypocalcemia.
Importance:
Moderate
Specific population safety: breastfeeding is not recommended due to potential infant hypocalcemia.
Importance:
Moderate
Administration specifics: administer only at end of hemodialysis treatment; do not administer missed doses; administer via venous line after hemodialysis during rinse back/after rinse back; do not mix/dilute prior to administration.
Importance:
High
Dose initiation details: recommended starting dose 5 mg IV bolus three times per week at end of hemodialysis.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Imprecision around “infusion” vs IV bolus and missing key dialysis-end administration instructions could lead to administration mismatch. Several important labeled safety elements (contraindications, key interaction/warning specifics, missed dose rule) were omitted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Administration details are not sufficiently label-accurate (bolus vs infusion; missing required dialysis-end/rinse-back and missed-dose instructions) and one limitation regarding non-hemodialysis CKD is misstated.
Suggested Improvement
Replace “infused”/“15 minutes” with label language (IV bolus injection; administered only at end of hemodialysis; via venous line after hemodialysis during rinse back/after rinse back; no missed doses). State the label limitation that PARSABIV has not been studied and is not recommended for CKD patients not on hemodialysis. Include contraindication and key interaction/safety wording.